Healthcare Industry News: image-guided
News Release - September 14, 2010
Clinical Experts Detail How They Use Varian's TrueBeam Technology to Improve the Precision and Speed of Cancer TreatmentsBARCELONA, Spain, Sept. 14 -- (Healthcare Sales & Marketing Network) -- Cancer treatment experts today reported their experiences with early treatments using the new TrueBeam system from Varian Medical Systems (NYSE:VAR ), aimed at increasing the speed and precision of radiotherapy and radiosurgery treatments. Clinicians from the first two European hospitals to start clinical treatments using the new TrueBeam system – Zurich University Hospital in Switzerland and VU University Medical Center in Amsterdam, Netherlands - addressed an Emerging Technologies Symposium at the annual ESTRO conference here in Barcelona to give detailed accounts of early patient treatments.
Professor Urs Luetolf of Zurich University Hospital said, "When we introduce new technology it is always interesting for our fellow radiation oncologists and radiation therapists to hear about clinical process improvements for treatment delivery and imaging which enables us to handle organ and tumor motion, but clinical medicine has one main goal – to add something for patient.
"We have treated more than 100 patients on the TrueBeam system since we introduced it six months ago and, although it's too early to assess outcomes, it's clear the system offers advantages in terms of the speed and precision of delivery," Prof. Luetolf added. "Cancer patients constantly seek a better cure and fewer side effects and they want to be treated using the latest and most advanced technology, and our experiences with this advanced system to date have been encouraging for patients as well as making the treatment process more straightforward for clinicians."
Professor Ben Slotman, head of radiation oncology at VU University Medical Center, outlined the results of patient treatments that commenced using the new TrueBeam system earlier this month, beginning with that of an 80-year-old lung cancer patient for whom surgery was deemed inappropriate because of her age and an earlier operation. She received eight stereotactic body radiosurgery treatments over a two-week period using TrueBeam in combination with RapidArc® technology and Professor Slotman described this pioneering treatment.
Professor Slotman also outlined key findings from two years of RapidArc radiotherapy treatments for more than 1,000 patients at VU, almost of third of them receiving hypo-fractionated, stereotactic body radiotherapy. "Delivering treatments rapidly is especially important when you need to deliver high doses with great precision, as shortening treatment times considerably reduces the extent of patient motion during treatment," he said.
During a presentation on "Emerging Clinical Applications in Radiosurgery", Dr. John Adler, Varian's chief of new clinical applications, spoke about the use of hypo-fractionation for a range of cancers as well as other lesions, tumors and conditions where radiosurgery may be indicated.
Designed to advance the treatment of lung, breast, prostate, head and neck, and other types of cancer, Varian's TrueBeam platform for image-guided radiotherapy and radiosurgery as introduced in April as the first fully-integrated system designed from the ground up to treat a moving target with unprecedented speed and accuracy.
Applicable for all forms of advanced external-beam radiotherapy including image-guided radiotherapy and radiosurgery (IGRT and IGRS), intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and RapidArc® radiotherapy, TrueBeam can deliver treatments with a dose delivery rate of up to 2400 monitor units per minute, double the maximum output of conventional systems. This makes it possible to offer greater patient comfort by shortening treatments, and to improve precision by leaving less time for tumor motion during dose delivery.
Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsLong-Term Results from SABR-COMET Further Demonstrate Effectiveness of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Metastatic Cancers
RaySearch Enters Into Interoperability Agreement With Varian
Varian Launches New Noona(R) Capabilities to Meet Growing Demand for Remote Cancer Patient Monitoring in Response to COVID-19's Impact on Healthcare